Blood vessel ageing and vascular memory

Česká verzia

Authors: Jan Václavík
Authors place of work: Centrum pro hypertenzi, I. interní klinika – kardiologická, FN a LF UP Olomouc
Published in the journal: Vnitř Lék 2020; 66(2): 104-110
Category:

Summary

As blood vessels age, their structure and function gradually change. This process is influenced by diet and the presence of modifiable risk factors. Blood vessel status can be clinically evaluated by measuring arterial stiffness or ankle-brachial index. The patient’s vascular age can be calculated using the SCORE project and indicates what age would have a person with the same calculated cardiovascular risk, whose risk factors were all within the normal range. The vascular age can be positively influenced by nonpharmacological measures, hypolipidemic statin therapy and also by hypertension pharmacotherapy, especially renin-angiotensin-aldosterone system inhibitors. Long-term follow-up of patients enrolled in clinical trials with antihypertensive and hypolipidemic agents suggests the existence of so-called vascular memory, since the beneficial effects of these interventions on reduction of cardiovascular morbidity and mortality persist for many years after completion of these studies. Early initiation of preventive measures has a greater effect.

Keywords:

intervention – vascular age – vascular aging – cardiovascular risk factors – metabolic memory – vascular memory

Zdroje

1. Barton M, Husmann M, Meyer MR. Accelerated Vascular Aging as a Paradigm for Hypertensive Vascular Disease: Prevention and Therapy. Can J Cardiol. 2016; 32(5): 680–686. e4. doi:10.1016/j.cjca.2016. 02. 062.

2. Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. The Role of Renin–Angiotensin–Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging. High Blood Press Cardiovasc Prev. 2018; 25(2): 137–145. doi: 10.1007/s40292-018-0252-5.

3. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. Atherosclerosis. 2015; 241(2): 507–532. doi:10.1016/j.atherosclerosis.2015. 05. 007.

4. Laurent S, Marais L, Boutouyrie P. The Noninvasive Assessment of Vascular Aging. Can J Cardiol. 2016; 32(5): 669–679. doi: 10.1016/j.cjca.2016. 01. 039.

5. Task A, Members F, Tendera M, et al. ESC GUIDELINES ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Document covering atherosclerotic disease of extracranial carotid The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Societ. 2011: 2851–2906. doi: 10.1093/eurheartj/ehr211.

6. Cuende JI, Cuende N, Calaveras -Lagartos J. How to calculate vascular age with the SCORE project scales: A new method of cardiovascular risk evaluation. Eur Heart J. 2010; 31(19): 2351–2358. doi: 10.1093/eurheartj/ehq205.

7. Cuende JI. La edad vascular frente al riesgo cardiovascular: aclarando conceptos. Rev Española Cardiol. 2016; 69(3): 243–246. doi: 10.1016/j.recesp.2015. 10. 022.

8. Vráblík M, Piťha J, Blaha V, et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. Hypertenze a KV prevence 2019; 2: 68–77.

9. Lopez -Gonzalez AA, Aguilo A, Frontera M, et al. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: A randomized trial. Eur J Prev Cardiol. 2015; 22(3): 389–396. doi:10.1177/2047487313518479.

10. Papakatsika S, Stabouli S, Antza C, Kotsis V. Early Vascular Aging: A New Target for Hypertension Treatment. Curr Pharm Des. 2015; 22(1): 122–126. doi: 10.2174/1381612822666151109112813.

11. Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short -term and long -term antihypertensive treatment: A meta -analysis of individual data in 294 patients. J Hypertens. 2011; 29(6): 1034–1042. doi: 10.1097/ HJH.0b013e328346a583.

12. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure -independent reduction in carotid stiffness after long -term angiotensin -converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006; 48(1): 80–86. doi: 10.1161/01.HYP.0000224283.76347.8c.

13. Kanaki AI, Sarafidis PA, Georgianos PI, et al. Effects of low -dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens. 2013; 26(5): 608–616. doi:10.1093/ajh/hps098.

14. Meng X, Qie L, Wang Y, Zhong M, Li L. Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity. Clin Investig Med. 2009; 32(6): 238–243.

15. Ballard KD, Taylor BA, Capizzi JA, Grimaldi AS, White CM, Thompson PD. Atorvastatin Treatment Does Not Alter Pulse Wave Velocity in Healthy Adults. Int Sch Res Not. 2014; 2014: 1–5. doi: 10.1155/2014/239575.

16. Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY -FIT study. J Am Coll Cardiol. 2014; 64(21): 2207–2217.

17. Nathan DM, Cleary PA, Backlund JYC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25): 2643–2653. doi: 10.1056/NEJMoa052187.

18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow -up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577–1589. doi: 10.1056/ NEJMoa0806470.

19. Simes J, Simes RJ, Hunt D, et al. Long -term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow -up. Lancet. 2002; 359(9315): 1379–1387. doi: 10.1016/ S0140-6736(02)08351-4.

20. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR. The Anglo -Scandinavian Cardiac Outcomes Trial: 11-year mortality follow -up of the lipid -lowering arm in the UK. Eur Heart J. 2011; 32(20): 2525–2532. doi: 10.1093/eurheartj/ehr333.

21. Bosch J, Lonn E, Pogue J, Arnold JMO, Dagenais GR, Yusuf S. Long -term effects of Ramipril on cardiovascular events and on diabetes: Results of the HOPE study extension. Circulation. 2005; 112(9): 1339–1346. doi: 10.1161/CIRCULATIONAHA.105.548461.

22. Gupta A, Mackay J, Whitehouse A, et al. Long -term mortality after blood pressure-lowering and lipid -lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow -up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127–1137. doi: 10.1016/S0140- 6736(18)31776-8.

23. Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016; 388: 2665–2712.